Followers | 298 |
Posts | 41114 |
Boards Moderated | 10 |
Alias Born | 08/30/2001 |
![](https://investorshub.advfn.com/uicon/8112.png?cb=1464282184)
Wednesday, November 24, 2021 12:04:47 PM
Item 1.01 Entry into a Material Definitive Agreement.
On November 24, 2021, Aditxt, Inc. (the “Company”) entered into a Warrant Reduction and Release Agreement (the “Warrant Reduction Agreement”) with certain investors (the “Investors”) that are the holders of warrants (the “Warrants”) issued in connection with the Securities Purchase Agreement dated as of August 25, 2021 by and between the Company and each of the Investors (the “Purchase Agreement”). Pursuant to the Warrant Reduction Agreement, the Company agreed to reduce the exercise price of the Warrants to $1.50 per share and to provide the Investors with a right to participate in certain future financings of the Company in consideration of the parties agreeing to certain mutual releases.
The foregoing description of the form of Warrant Reduction Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Warrant Reduction Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Full filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1726711/000121390021061795/ea151351-8k_aditxtinc.htm
PROTECT YOUR ASS-ets!!
Recent ADTX News
- Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 • Business Wire • 08/29/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 08:30:21 PM
- Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) • Business Wire • 08/26/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:44:14 PM
- Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics • Business Wire • 08/21/2024 12:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:16:12 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:15:25 PM
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 • PR Newswire (US) • 08/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:15:09 PM
- Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans • Business Wire • 08/13/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:15:21 PM
- Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules • Business Wire • 08/09/2024 08:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 02:28:09 PM
- Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules • Business Wire • 08/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:44:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:03:52 AM
- Biotech Soars Despite Broader Selloff • AllPennyStocks.com • 08/07/2024 07:25:00 PM
- Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer • Business Wire • 08/07/2024 12:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/07/2024 04:15:16 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:15:15 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:15:13 PM
- Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st • GlobeNewswire Inc. • 07/25/2024 01:00:00 PM
- Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition • Business Wire • 07/25/2024 12:30:00 PM
- Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 • PR Newswire (US) • 07/23/2024 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 08:15:08 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM